SCHEMBL2497578

SCHEMBL2497578

O=[C]c1ccc2c(c1)C=CC2

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2856442 0.84 CA1 (0.30) CA1CA2
SCHEMBL15876269 0.83 CA1 (0.35) CA1CA2
SCHEMBL23100785 0.80 CA1 (0.33) CA1CA2
SCHEMBL148119 0.80 CA1 (0.44) CA1CA2
SCHEMBL275807 0.74 CA1 (0.33) CA1CA2
SCHEMBL998768 0.73 GSK3A (0.36)
SCHEMBL23100763 0.73
SCHEMBL2179938 0.72 MAPK1 (0.43) CA1CA2
SCHEMBL9629684 0.72 CA1 (0.34) CA1CA2
Trifluoroacetic Acid SCHEMBL23783075 0.71 PTGS2 (0.40) CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2106855-B1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst NISSAN CHEMICAL IND LTD (JP) 2012-07-11 EP disclosed
US-8030499-B2 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-10-04 US disclosed
US-7851503-B2 Thrombopoetin receptor activator and process for producing the same NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-12-14 US disclosed
US-7700789-B2 Heterogeneous catalyst and process for producing oxirane compound with the catalyst NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-04-20 US disclosed
EP-1632291-B1 HETEROGENEOUS CATALYST AND PROCESS FOR PRODUCING OXIRANE COMPOUND WITH THE CATALYST NISSAN CHEMICAL IND LTD (JP) 2009-12-16 EP disclosed
EP-2106855-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst Nissan Chemical Industries, Ltd. (JP) 2009-10-07 EP disclosed
US-20090082583-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-03-26 US disclosed
US-20080318923-A1 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-25 US disclosed
US-20070093667-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2007-04-26 US disclosed
EP-1632291-A1 HETEROGENEOUS CATALYST AND PROCESS FOR PRODUCING OXIRANE COMPOUND WITH THE CATALYST Nissan Chemical Industries, Ltd. (JP) 2006-03-08 EP disclosed
US-20050282730-A1 Thrombopoetin receptor activator and process for producing the same NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2005-12-22 US disclosed
EP-1552828-A1 THROMBOPOETIN RECEPTOR ACTIVATOR AND PROCESS FOR PRODUCING THE SAME Nissan Chemical Industries, Ltd. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093667-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst OXGR1, OXER1, OGFOD1 CA1 181/4885CA2 232/4885
US-20090082583-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst OXGR1, OGFOD1, OGDH CA1 196/4885CA2 229/4885
US-20050282730-A1 Thrombopoetin receptor activator and process for producing the same PDGFRA, PTAFR, TBXA2R CA1 4458/4885CA2 4434/4885
US-20080318923-A1 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle AVPR1B, AVPR1A, AVPR2 CA1 2198/4885CA2 3439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.